These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15930273)

  • 21. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
    Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
    Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
    Isakoff SJ; Engelman JA; Irie HY; Luo J; Brachmann SM; Pearline RV; Cantley LC; Brugge JS
    Cancer Res; 2005 Dec; 65(23):10992-1000. PubMed ID: 16322248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.
    Chaudhari A; Krumlinde D; Lundqvist A; Akyürek LM; Bandaru S; Skålén K; Ståhlman M; Borén J; Wettergren Y; Ejeskär K; Rotter Sopasakis V
    Mol Cell Biol; 2015 Oct; 35(19):3258-73. PubMed ID: 26169833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
    Ghodsinia AA; Lego JMT; Garcia RL
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
    Kang S; Bader AG; Vogt PK
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):802-7. PubMed ID: 15647370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic deregulation of the PIK3CA oncogene in oral cancer.
    Murugan AK; Munirajan AK; Tsuchida N
    Cancer Lett; 2013 Sep; 338(2):193-203. PubMed ID: 23597702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rare cancer-specific mutations in PIK3CA show gain of function.
    Gymnopoulos M; Elsliger MA; Vogt PK
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5569-74. PubMed ID: 17376864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
    Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
    Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of Lipid Alterations by Oncogenic
    Jung JH; Yang DQ; Song H; Wang X; Wu X; Kim KP; Pandey A; Byeon SK
    OMICS; 2023 Jul; 27(7):327-335. PubMed ID: 37463468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
    Kinross KM; Montgomery KG; Mangiafico SP; Hare LM; Kleinschmidt M; Bywater MJ; Poulton IJ; Vrahnas C; Henneicke H; Malaterre J; Waring PM; Cullinane C; Sims NA; McArthur GA; Andrikopoulos S; Phillips WA
    FASEB J; 2015 Apr; 29(4):1426-34. PubMed ID: 25550458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
    Koren S; Bentires-Alj M
    FEBS J; 2013 Jun; 280(12):2758-65. PubMed ID: 23384338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Jun; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
    Hare LM; Schwarz Q; Wiszniak S; Gurung R; Montgomery KG; Mitchell CA; Phillips WA
    Dev Biol; 2015 Aug; 404(1):14-26. PubMed ID: 25958091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
    Zhang H; Liu G; Dziubinski M; Yang Z; Ethier SP; Wu G
    Breast Cancer Res Treat; 2008 Nov; 112(2):217-27. PubMed ID: 18074223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K).
    Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R
    J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.